Dr. Hongbo Lu, is a Managing Partner with Lilly Asia Ventures (LAV). Prior to joining LAV, Dr. Lu served as a Managing Director at OrbiMed Advisors and spearheaded the efforts in building a billion-dollar emerging market hedge fund portfolio for the firm between 2011 – 2016. Dr. Lu has close to 20 years of investment and operational experience in the healthcare industry. She served or is serving on multiple company boards including CrownBio (acquired by JSR), Turing Point Therapeutics (NASDAQ IPO), Avedro (NASDAQ IPO and acquired by Glaukos), Echosens, PINS, among others. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University.